172@29@17@143!~!172@29@0@53!~!|news|business|stocks|astrazeneca-pharma-rises-4-on-permission-from-dcgi-4477331.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to Moneycontrol Pro and get 365 bonus InterMiles! Use Code: INTERMILES
Last Updated : Sep 26, 2019 12:06 PM IST | Source: Moneycontrol.com

AstraZeneca Pharma rises 4% on permission from DCGI

The receipt of this permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN) in India.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Share price of AstraZeneca Pharma rose more than 4 percent on September 26 after company received permission from the Drugs Controller General of India (DCGI).

The company in its press release said that it has received import and market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets.

The receipt of this permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film-coated tablets (QTERN) in India, subject to the receipt of other related statutory approvals and licenses.

Close

FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

At 1148 hrs, AstraZeneca Pharma was quoting at Rs 2,245.95, up Rs 94.25, or 4.38 percent on the BSE.
First Published on Sep 26, 2019 12:06 pm
Sections